Sunny Delight testing the waters with new juice drink
CINCINNATI — Sunny Delight Beverages Co. announced that it would be testing a carbonated juice drink aimed at consumers looking for an alternative to energy drinks. The product, SunnyD X, is currently available in independent convenience stores and select grocery stores in Boston, Philadelphia and Washington, D.C.
"SunnyD X offers more than the intense taste and 100% Vitamin C you would expect — it also offers a different kind of pick-me-up — carbonated energy that is uniquely provided by a combination of three carbohydrates, as well as seven B-vitamins to help metabolize the carbohydrates into energy," said David Zellen, associate marketing director. "Simply put, SunnyD X offers the energy teens crave without the ingredients moms tell us concern them, such as caffeine and taurine. It’s a win-win."
SunnyD X is available in a 16-oz. can and comes in three flavors: orange, lemon line and fruit punch. The marketing plan for the beverage includes sampling at venues and locations of interest to teens, like concerts, sporting events, skate parks and beaches. A new website, SunnyDX.com, also will be utilized.
Report: Proposed ballot measure aims to change North Dakota pharmacy law
BISMARK, N.D. — In North Dakota, a proposed ballot measure is on the table that, if approved, would repeal a 50-year-old section of state law that requires pharmacies to be majority-owned by pharmacists who are licensed in North Dakota, according to a local news report.
North Dakota is the only state in the country with such a requirement and has similar ownership laws for professions such as optometry and dentistry, the Jamestown Sun reported.
The law essentially bans chain retailers like Walgreens and Wal-Mart from operating pharmacies in the state. However, there are some exceptions, including a grandfather clause for chains such as CVS/pharmacy that were in place in North Dakota before July 1, 1963, the article stated.
In order to get the measure on the Nov. 4 ballot, sponsors need 13,452 signatures by Aug. 6, the article stated.
In 2010, proponents gathered nearly 14,000 signatures for a similar measure but Secretary of State Al Jaeger rejected the petitions on a technical error because they with the list of petition sponsors, according to the report.
Mylan settles patent litigation related to Celebrex capsules
PITTSBURGH — Mylan announced on Monday that it has entered into a settlement and license agreement with Pfizer relating to Mylan’s abbreviated new drug application filed with the U.S. Food and Drug Administration for celecoxib capsules, 50-mg, 100-mg, 200-mg and 400-mg strengths.
This product is the generic version of Celebrex, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Under the terms of the agreement, Mylan will begin selling product at the earliest market formation, however, in any case not later than December. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission, Mylan stated.
In addition, Mylan has appealed the decision by the United States District Court for the Northern District of West Virginia denying Mylan’s request for an injunction in its suit against the FDA. Mylan continues to believe that the FDA “seriously erred” in its decision awarding one-party eligibility for 180 days of exclusivity on celecoxib, and will continue with this suit independent of the aforementioned settlement, the company stated.
As reported by Drug Store News, the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex (celecoxib) 100-, 200- and 400-mg capsules
For the 12 months ended March 31, 2014, Celebrex had U.S. sales of approximately $2.34 billion, according to IMS Health.